LABTWIN
14.12.2022 12:01:42 CET | Business Wire | Press release
Today, Royal DSM N.V., a global company specializing in health, nutrition, and sustainable living, and LabTwin GmbH, the leading voice and AI-powered digital lab assistant, announce a multi-year license and collaboration agreement. DSM will apply the newly acquired technology in several of their Science & Innovation laboratories globally. Together, we intend to transform how science is performed in research and application labs providing significant value through speeding up innovation cycles at DSM and its partners worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221214005030/en/
DSM partners with LabTwin to empower scientists with the latest voice and AI solutions. (Graphic: Business Wire)
“We are excited to see that LabTwin is already onboarded on multiple of DSM’s R&D premises globally with more than 100 scientists and technicians, and we are looking forward to supporting them further in their digital transformation journey,” said Magdalena Paluch, CEO of LabTwin.
LabTwin’s digital lab assistant enables hands-free data capture through voice notes or connected lab instruments while working at the bench and provides on-the-go access to safety or operational information. LabTwin also talks scientists through protocols and records any deviations or out of specification results. This data is then automatically structured by LabTwin’s deep learning capabilities and enriched with metadata. The digital assistant will form part of DSM’s wider digitalization strategy, including the full integration with DSM’s Electronic Lab Notebooks.
Willi Gottstein, Scientist and Project Manager at DSM explains “LabTwin has already become the digital assistant of many of our experimentalists, leading to better data and result tracking in the lab, FAIR data processing and more efficient reporting in the office. LabTwin significantly lowers the threshold to record observations leading to higher reproducibility of experiments and easier trouble-shooting.”. Hans Roubos, Director Digital Science and Technologies at DSM continues: “LabTwin offers us a Siri-like experience for the Lab with many options for further advancing our lab operations, from guiding our scientists through laboratory protocols to interacting with labware and storing data and observations in a smart, hands-free way”.
Both DSM and LabTwin shall provide more details on this exciting collaboration in the coming year.
Watch this short product tour video to learn more about LabTwin or follow us on LinkedIn.
LabTwin
LabTwin is creating the next generation of digital lab tools for smart labs, starting with the world's first voice-activated lab assistant. With LabTwin, scientists can collect data, access information, manage experiments and streamline documentation simply by talking. Using voice recognition and machine learning technology, LabTwin’s smart assistant simplifies data capture, structures valuable information, and provides suggestions to scientists in real-time so they can make more informed data-driven decisions. LabTwin is backed by BCG Digital Ventures and Sartorius. Its voice-powered assistant is used in chemical companies and in 7 of the Top20 Pharma around the world.
DSM – Bright Science. Brighter Living. ™
Royal DSM is a global science-based company active in health & nutrition. DSM is organized in three Business Groups: Food & Beverage, Health Nutrition & Care, and Animal Nutrition & Health. Our long-term success in serving these markets require innovations that are customer-focused, value-adding and differentiating and, at the same time, grounded in market insights as well as best-in-class launch execution capabilities. DSM and its associated companies deliver an annual net sales of about €10 billion with approximately 25,000 employees. More information can be found at www.dsm.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005030/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom